These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 29022654)

  • 1. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valbenazine for Tardive Dyskinesia.
    Freudenreich O; Remington G
    Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
    McEvoy JP
    J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.